Citi analyst Joanne Wuensch downgraded Glaukos to Neutral from Buy with a price target of $132, up from $130. While the firm continues to anticipate a successful iDose launch and upside to estimates, it believes these expectations are well in the stock. Citi is stepping to the sidelines “given the tremendous run” in the shares over the past 18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: